Industry

At ARVO 2026 in Denver, Myopia Management and AI Take Center Stage

Vision Monday1d ago1 min read

DENVER—The Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting was held here May 3–7 with a focus on "Achieving Precision Ophthalmology Through Innovative Vision Research." The annual conference drew nearly 11,000 attendees from 72 countries and explored advances in artificial intelligence (AI), sustainable retinal therapies, and myopia control, among other topics, according to show organizers. Several companies in the vision and medtech space took part in the annual conference, with many showing their new wares and presenting peer-reviewed research and poster sessions at the five-day event.

Read full article on Vision Monday

AI Summary

Quick Take

The ARVO 2026 Annual Meeting in Denver convened nearly 11,000 global experts to advance 'Precision Ophthalmology,' with a heavy emphasis on artificial intelligence, myopia control, and sustainable retinal therapies. The five-day event served as a primary launchpad for new medtech innovations and peer-reviewed research aimed at personalizing patient care.

Why It Matters

The focus on precision ophthalmology signals a transition from one-size-fits-all treatments to data-driven, individualized care models. By prioritizing AI and myopia management, the research community is addressing the industry's most urgent needs: managing the global myopia epidemic and integrating machine learning into daily diagnostics. For the practicing clinician, these developments represent the next wave of standard-of-care tools that will likely dictate treatment protocols for the remainder of the decade.

Key Details

The meeting attracted approximately 11,000 attendees from 72 different countries, highlighting a global shift toward collaborative vision research.
Artificial intelligence was a primary focus, specifically regarding its role in achieving higher diagnostic precision and refining treatment outcomes.
Myopia management research continues to expand, with significant attention paid to new control strategies and clinical data.
Sustainable retinal therapies were highlighted as a critical area of innovation, focusing on long-term management of posterior segment diseases.
The event integrated commercial medtech exhibitions with rigorous peer-reviewed poster sessions and research presentations.

Practice Implications

Clinicians should anticipate a more rapid integration of AI-driven diagnostic software and a broader range of evidence-based myopia control options in the near future. The emphasis on sustainable retinal therapies suggests that the next generation of treatments may focus on reducing patient burden through longer-acting delivery systems or more efficient dosing schedules.

Who's Affected

OphthalmologistsOptometristsRetina SpecialistsPediatric OptometristsVision ResearchersPractice Owners

Evidence StrengthModerate

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.